From the *Service de Médecine Nucléaire, CHU; †Service de Médecine Nucléaire, CLB; ‡Service d'Endocrinologie, Groupement Hospitalier Est, CHU; §Service de Chirurgie Endocrinienne, Groupement Hospitalier Sud, CHU; ∥Unité de Dermatologie, CLB; and ¶EA 3637, Université de Lyon 1, Lyon, France.
Clin Nucl Med. 2017 May;42(5):379-382. doi: 10.1097/RLU.0000000000001636.
F-FDOPA is a well-established tool to explore pheochromocytomas. It tends to replace I-MIBG scan in metastatic pheochromocytomas, multiple endocrine neoplasia type 2-related tumors, succinate dehydrogenase [ubiquinone] iron-sulfur subunit-negative tumors, and succinate dehydrogenase[ZERO WIDTH SPACE]-positive lesions. To our knowledge, no study has characterized physiological and pathological adrenal glands with F-FDOPA from a quantitative point of view. We report the features of different normal and pathological adrenal glands with F-FDOPA. Within our series, only pheochromocytomas present a significantly increased uptake reflecting the high specificity of this tracer. Tumors such as adenomas or myelolipomas present no F-FDOPA significant accumulation. Interestingly, adrenal gland hyperplasia and solitary glands do not demonstrate compensatory uptake.
F-FDOPA 是一种被广泛应用的工具，可用于研究嗜铬细胞瘤。它往往可以替代 I-MIBG 扫描，用于转移性嗜铬细胞瘤、多发性内分泌肿瘤 2 型相关肿瘤、琥珀酸脱氢酶[泛醌]铁硫亚基阴性肿瘤和琥珀酸脱氢酶[零宽度空间]阳性病变。据我们所知，尚无研究从定量角度描述过 F-FDOPA 对正常和病理性肾上腺的特征。我们报告了 F-FDOPA 对不同正常和病理性肾上腺的特征。在我们的研究中，只有嗜铬细胞瘤表现出明显的摄取增加，反映了这种示踪剂的高度特异性。例如腺瘤或骨髓脂肪瘤等肿瘤则没有明显的 F-FDOPA 聚集。有趣的是，肾上腺增生和孤立的腺体并没有表现出代偿性摄取。
